Ibio, Inc. · NASDAQ:IBIO
Ibio — Investor Presentation (March 2022)
30 slides from Ibio's investor presentation, Mar 18, 2022
Slide 1: Growing Tomorrow's Biologics Corporate Presentation
Growing Tomorrow’s Biologics CORPORATE PRESENTATION March 2022 Tom Isett, Chairman & CEO © 2022 iBio , Inc. All Rights Reserved.
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements Certain statements in this presentation constitute "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended .. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "
Slide 3: iBio: Growing Tomorrow's Biologics
iBio : Growing Tomorrow’s Biologics Discovery Platform Novel screening capabilities with AI - driven design FastPharming Platform Proprietary plant - based protein expression system Development & Manufacturing Services Delivering speed, scalability, and sustainability Proprietary Pipeline Addressing
Slide 4: Unique Solution for Some of the Industry's Biggest Problems
Only ~5 in 5,000 drug concepts reach the clinic Program Failures 4 Unique Solution for Some of the Industry’s Biggest Problems 1i iBio estimates; 2 Belkhir, L., et. al. (2018) “Carbon footprint of the global pharmaceutical industry and relative impact of its major players” .. J Cleaner Production 21
Slide 5: Green Protein Expression System
5 Green Protein Expression System 130,000 sf Facility 1 Bacterial Infiltration (Transient Transfection) Protein Production Harvesting Purification & Vialing Seeding & Growth Mobilization Gene Cloning 2 3 4 5
Slide 6: The Speed & Scalability of FastPharming
6 The Speed & Scalability of FastPharming Potentially Enables a Faster, More Efficient Path to the Clinic Time to Drug Substance may vary and does not include product - specific process and assay development work. Mammalian cell culture timelines shown are for illustrative purposes only based upon c
Slide 7: iBio Platforms Enable More Promising Candidates to Reach the Clinic, Faster
7 iBio Platforms Potentially Enable More Promising Candidates to Reach the Clinic, Faster Industry Benchmarks to Reach IND 1 Success Rate: <5 in 5,000 Time: >5 Years Cost: >$20M Current Drug Development Challenge Drug Discovery Preclinical 3 - 6 Years FDA Review Scale - up to MFG Post - Marketing Su
Slide 8: FastPharming: Reducing Single-Use Plastic Disposables in Bioprocessing
8 1 17th Annual Report and Summary of Biopharmaceutical Manufacturing Capacity and Production https://www.biopharma.com/TRENDS.pdf .. 2 Seeds, stone wool, and purified water FastPharming : Reducing Single - Use Plastic Disposables in Bioprocessing The FastPharming Expression System uses all - natura
Slide 9: Our Platform Technologies Fueling a Growing Pipeline
9 Our Platform Technologies Fueling a Growing Pipeline
Slide 10: Therapeutics: Oncology & Fibrosis
Therapeutics Oncology & Fibrosis
Slide 11: RTX-003 (IBIO-101) Stimulates Anti-tumor Immunity via anti-CD25 Treg Depletion
THERAPEUTICS Natural Killer Cell Indiscriminate depletion of T reg + T eff RTX - 003 (IBIO - 101) Stimulates Anti - tumor Immunity via anti - CD25 T reg Depletion 11 T reg = Regulatory T Cells; T eff = Effector T Cells; ADCC = Antibody Dependent Cellular Cytotoxicity T eff JAK JAK 1 st gen anti - CD
Slide 12: RTX-003 Inhibits Tumor Growth, Alone and in Combination
THERAPEUTICS 12 RTX - 003 Inhibits Tumor Growth, Alone and in Combination 1 In vivo xenograft mouse model of lymphoma; Administration: 3x / week, i.p. ; n=5 per group 2 In vivo transgenic hCD25 mouse model; Admin: i.p. 3X / week at a single dose (1.5 mg/Kg) in combination with 2.5 mg/Kg of anti - mo
Slide 13: Deploying AI-based Target ID & Glycaneering in Immuno-Oncology
THERAPEUTICS 13 Deploying AI - based Target ID & Glycaneering in Immuno - Oncology to Create More, Higher - Quality, Shots - on - Goal Speed - to - Clinic & Readily Scalable Access to RubrYc AI Discovery Platform Glycaneering Technology As programs advance through preclinical testing, iBio has addit
Slide 14: IBIO-100: Promising Anti-Fibrotic Therapeutic Candidate
THERAPEUTICS 14 IBIO - 100: Promising Anti - Fibrotic Therapeutic Candidate 1 Idiopathic Pulmonary Fibrosis: Disease Landscape & Forecast, Decision Resources, April 6, 2020; 2 iBio data on file Involved in ~45% of U.S. deaths from all diseases No cures: organ transplants for some late - stage diseas
Slide 15: Vaccines: Human Health: COVID-19; Animal Health: CSFV
Vaccines Human Health: COVID - 19 Animal Health: CSFV
Slide 16: The Pandemic Continues
VACCINES 16 COVID - 19 1 Johns Hopkins Coronavirus Resource Center (accessed 16 March 2022) …while experts sound the alarm “V accination strategies based on repeated booster doses of the original vaccine composition are unlikely to be appropriate or sustainable." Boosters are “not something that sho
Slide 17: Experts Calling for Approaches Like iBio's DAVi Vaccine Design
VACCINES Lower cost vaccines & alternative routes of administration 17 Experts Calling for Approaches Like iBio’s “ DAVi ” Vaccine Design 1 Borio , Bright, and Emanuel, A National Strategy for COVID - 19 Medical Countermeasures , JAMA. 2022;327(3):215 – 216 Second - generation IBIO - 202 development
Slide 18: IBIO-202 Nucleocapsid-based Subunit Vaccine
VACCINES 18 IBIO - 202 Nucleocapsid [N] - based Subunit Vaccine May Complement to Current and Future Spike [S] - based Vaccines 1 Dai, L. & Gao, G. F. Viral targets for vaccines against COVID - 19. Nature Reviews Immunology 21, 73 – 82 (2021); 2 Fielding CA, et.al .., ADNKA overcomes SARS - CoV2 - m
Slide 19: IBIO-202 Preclinical Data Shows Protective Immune Responses
VACCINES 19 IBIO - 202 Preclinical Data Shows Potential for Protective Humoral & Cell - mediated Immune Responses C t r l .. I B I O - 2 0 2 0 1 2 3 4 I F N - g S e c r e t i n g c e l l s / 1 0 6 ✱✱✱✱ High number of N - specific IFN g secreting T cells indicates immune activation C t r l .. I B I O
Slide 20: Emerging Studies Reinforce Value of IBIO-202's Design
VACCINES 20 Emerging Studies Reinforce Value of IBIO - 202’s Design 1 Kundu, R., Narean, J.S., Wang, L. et al. Cross - reactive memory T cells associate with protection against SARS - CoV - 2 infection in COVID - 19 contacts. Nat Commun 13, 8 0 (2022) 2 Cohen, et al. Cell Reports Medicine. July 2021
Slide 21: IBIO-202 Appears Differentiated in a Crowded Field
VACCINES 9 4 2 1 N only (US & global companies) ■ N only (academic, government, ex - US) ■ S+N+M or other combination ■ S+N 21 IBIO - 202 Appears Differentiated in a Crowded Field 1 Dangi, Tanushree et al. “Combining spike - and nucleocapsid - based vaccines improves distal control of SARS - CoV - 2
Slide 22: Classical Swine Fever Animal Health
Classical Swine Fever Animal Health
Slide 23: Classical Swine Fever is a Significant Worldwide Economic Burden
VACCINES 23 Classical Swine Fever [CSF] is a Significant World - Wide Economic Burden and Puts Major Export Markets at Risk • CSF is a priority agricultural biothreat • CSF poses a risk to $7.0B US swine exports • Only 38 countries are currently CSF - free • No vaccines are approved in the US (only
Slide 24: IBIO-400 Offers Potential Benefits Over Current Alternatives
VACCINES 24 IBIO - 400 Offers Potential Benefits Over Current Alternatives • Provides single - dose protection against CSF • Is a low - cost alternative to current recombinant vaccines • Supports important trade requirements, unlike live virus vaccines • Potential to be the first CSF vaccine fully l
Slide 25: iBio
iBio e ie} £ £ 5 a £
Slide 26: Our Leadership Team Brings Drug Development & Bioprocessing Experience
Our Leadership Team Brings Drug Development & Bioprocessing Experience 26 Tom Isett CEO & Chairman Martin Brenner , DVM, Ph.D. CSO Robert Lutz, MBA CFBO Randy Maddux , MBA COO Lisa Middlebrook CHRO
Slide 27: Strong and Growing IP Estate Provides Exclusivity for iBio's Pipeline
27 Strong and Growing IP Estate Provides Exclusivity for iBio’s Pipeline Issued Patents (30 U.S.) 104 Active Applications (10 U.S.) 29 More Applications progressing to filing Patent Protection Includes: • IP for iBio’s pipeline products and vaccines • IP related to the FastPharming Protein Expressio
Slide 28: Financial Overview
28 Financial Overview § Publicly traded (NYSEA: IBIO) since Jan 2008 § Approximately $57.4M in cash and cash equivalents plus investments in debt securities, excluding $5.9M of restricted cash (31 Dec 2021) § Approximately 218.0M common shares & 17M options, restricted stock units and warrants outst
Slide 29: Upcoming Milestones
29 Upcoming Milestones Human Health Program Next Milestone Subsequent Key Milestone IBIO - 400 Oral immunogenicity study results USDA Manufacturing Clearance Program Next Milestone Subsequent Key Milestone IBIO - 100 Completion of lead optimization IND - Enabling Study Initiation IBIO - 101 IND - en
Slide 30: iBio: Leveraging Capabilities to Create Shareholder Value
30 iBio : Leveraging Capabilities to Create Shareholder Value Advancing our proprietary pipeline with FastPharming Manufacturing Partnering Providing better options for the $6B Bioprocess industry CDMO Services Vaccines Therapeutics Partnering Leveraging platform to seek attractive assets for in - l